» Articles » PMID: 31621624

Feasibility of Repeat and Bilateral Submandibular Gland Needle Biopsies in Parkinson's Disease

Overview
Specialty Neurology
Date 2019 Oct 18
PMID 31621624
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Submandibular gland (SMG) biopsies detect pathological alpha-synuclein (aSyn) in patients with Parkinson's disease (PD). The objectives of this study were to determine 1) the feasibility of performing a second SMG biopsy in previously biopsied patients, 2) the feasibility of doing bilateral SMG biopsies, 3) laterality of aSyn density, 4) whether aSyn density changes over time.

Methods: Seven PD patients (6 males) previously having positive unilateral SMG biopsies underwent bilateral needle biopsies. Staining with a validated antibody to pathologic p-serine 129 aSyn was performed.

Results: Mean age at time of second biopsy was 76 years and mean time between biopsies was 4.1 years. Five subjects had sufficient SMG tissue bilaterally and two only unilaterally for a total of 12/14 glands biopsied having sufficient tissue, all 7 subjects having sufficient tissue on at least one side, and all 12 glands being aSyn positive. There was a 4x increase in aSyn density on average in the repeat biopsy, with 5 subjects having an increase, one no change, and one a decrease in density. Side effects were similar to previous reports; mainly bruising, swelling, slight bleeding.

Conclusions: This is the first published study of bilateral transcutaneous needle biopsies of the SMG in living patients with PD which showed better tissue acquisition and a change in aSyn density over time. While further study is needed, there is potential for SMG biopsies to serve as a tissue biomarker for PD disease progression and potentially as a peripheral outcome measure for anti-aSyn treatment.

Citing Articles

Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.


Peripheral cutaneous synucleinopathy characteristics in genetic Parkinson's disease.

Yuan Y, Wang Y, Liu M, Luo H, Liu X, Li L Front Neurol. 2024; 15:1404492.

PMID: 38751879 PMC: 11094647. DOI: 10.3389/fneur.2024.1404492.


Symmetry of synuclein density in autopsied Parkinson's disease submandibular glands.

Adler C, Serrano G, Shill H, Driver-Dunckley E, Mehta S, Zhang N Neurosci Lett. 2024; 825:137702.

PMID: 38395191 PMC: 10942751. DOI: 10.1016/j.neulet.2024.137702.


Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.

Jimenez-Jimenez F, Alonso-Navarro H, Garcia-Martin E, Santos-Garcia D, Martinez-Valbuena I, Agundez J Biomolecules. 2023; 13(8).

PMID: 37627328 PMC: 10452242. DOI: 10.3390/biom13081263.


Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.

Angius F, Mocci I, Ercoli T, Loy F, Fadda L, Palmas M J Neurol. 2023; 270(11):5613-5621.

PMID: 37552278 PMC: 10576686. DOI: 10.1007/s00415-023-11893-x.


References
1.
Beach T, Serrano G, Kremer T, Canamero M, Dziadek S, Sade H . Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol. 2018; 77(9):793-802. PMC: 6097838. DOI: 10.1093/jnen/nly056. View

2.
Adler C, Beach T, Hentz J, Shill H, Caviness J, Driver-Dunckley E . Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014; 83(5):406-12. PMC: 4132570. DOI: 10.1212/WNL.0000000000000641. View

3.
Beach T, Adler C, Serrano G, Sue L, Walker D, Dugger B . Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. J Parkinsons Dis. 2016; 6(1):153-63. PMC: 5498170. DOI: 10.3233/JPD-150680. View

4.
Walker D, Lue L, Adler C, Shill H, Caviness J, Sabbagh M . Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2012; 240:190-204. PMC: 3720241. DOI: 10.1016/j.expneurol.2012.11.020. View

5.
Beach T, White C, Hamilton R, Duda J, Iwatsubo T, Dickson D . Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008; 116(3):277-88. PMC: 2708176. DOI: 10.1007/s00401-008-0409-8. View